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BIOTECHNOLOGY AND THE AFRICAN FARMER 
 
“Those who reject biotechnology do so on full stomachs.” 




Africa is a hungry continent and the poorest, most food insecure 
region of the world. Its bleak prospects for improving food security 
raise two critical political economy questions: why are most African 
governments underinvesting in the essentials for a modern and 
productive agriculture, failing to build scientific capacity, roads, dams, 
schools, and universities of agriculture and ignoring such essential 
micro details as security of tenure and efficient input and product 
markets? In stark contrast to Africa, why are Asian governments such 
as China, India and the Philippines investing heavily in agricultural 
biotechnology
1 when they have grain surpluses (India has 50 million 
tons of grain in storage), while most food deficient countries in Africa 
are fearful of supporting and investing in the gene revolution?  
 
Simple facts tell the story.  Commercialization of genetically modified 
(GM) or transgenic crops, now often called biotech crops, was first 
approved for use in 1995 by farmers in the United States, Mexico and 
Australia. However, after a decade of rapid growth of GM crops, most 
governments in Africa are watching the gene revolution pass it by. 
Currently, South Africa is the only one of the 53 countries on the 
African continent that is growing GM crops (James 2004).
2  
 
Two examples show that biotech crops are facing a number of 
                                                 
1 We have adopted FAO’s definition of agricultural biotechnology as follows: Agricultural biotechnology encompasses 
a range of research tools scientists use to understand and manipulate the genetic make-up of organisms for use in 
agriculture: crops, livestock, forestry and fisheries. Biotechnology is much broader than genetic engineering and 
includes tissue culture, genomics and bioinformatics, marker-assisted selection, micro-propagation, cloning, artificial 
insemination, embryo transfers and other technologies (FAO 2004, p.4.). We assume most countries in Africa are using 
tissue culture in their research. 
2 South Africa’s journey into biotech crops started in 1978 when a government committee, SAGENE, drafted biosafety 
guidelines. The government field tested Bt cotton in 1990 and commercialized it in 1997 followed by soybeans in 2000 
(James 2004).   5
complex and  unforeseen barriers to adoption in Africa. In 1991 the 
Monsanto Company offered to transfer GM sweet potato technology 
to the government of Kenya on a royalty-free basis. After fourteen 
years of research this public – private partnership has been unable to 
develop GM sweet potatoes and secure biosafety regulatory approval 
to release them to smallholders. The second example is potato 
research, in Egypt and subsequently in South Africa. In 1993, 
Michigan State University and Egyptian researchers formed a 
partnership to develop Bt potatoes for smallholders in Egypt. After 
eight years of research, the government of Egypt terminated the 
research agreement for fear that the planting of the Bt potato 
(Spunta1) might jeopardize its future potato exports to Europe 
(because of the EU’s positon on GM crops). In 2001 the Michigan 
State potato researchers then shifted their effort to South Africa, but 
after four years of joint research, some new regulatory concerns still 
need to be addressed. To summarize, 12 years of time and $3 million 
of donor support have been unable to deliver GM potatoes to 
smallholder farmers in either Egypt or South Africa. These and other 
examples highlighted in the seven case studies in this paper illustrate 
the unexpected barriers and the time required to develop and release 
GM crops and get them approved for release to farmers in Africa. It is 
easy to understand why multinational firms are not investing in 
biotech research on crops with small markets such as teff, cowpea 
and millet (deVries and Toenniessen 2001). But why have public 
scientists in NARS and the CGIAR been unable to develop GM 
maize, cassava, sorghum (Africa’s main food staples)? Why does the 
CGIAR only allocate around 10 percent of its global budget to GM 
crop and animal vaccine research? 
 
Ten years ago, farmers in the United States, Mexico and Australia were 
authorized by their governments to grow GM crops.
 3 Since then the growth 
of GM crops has mushroomed, growing by 20 percent in 2004 alone (James 
2004). However, the historical record on the growth and expansion of 
biotech crops highlights one startling statistic: GM crop growth has taken 
root in many regions of the world except in Europe and Africa.  
 
The origins of African policy makers’ concern over biotechnology are 
                                                 
3 See James (2004) for a global report on GM crops; Trigo et al (2002) for a discussion of GM growth in Latin 
America; Qaim and Matusche (2004) for a global survey and Kelemu et al (2004) for an up to date inventory of biotech 
research in Africa.   6
partially a spillover from concerns in Europe about food safety, the 
environment and generalized public mistrust of multi national as being 
manipulative and unscrupulous. The transplanting of European consumer 
concerns coincided with a regional drought in Southern Africa in 2002/3/4 
that required a large amount of food aid. The main supplier of food aid was 
the United States, which did not have “identity-preserved supply chains”
4 for 
most of the GM and non-GM maize. Hence African governments become 
concerned about the potential health, environmental and trade effects of 
importing food aid. The lack of biosafety regulations and the capacity to 
evaluate GM and non-GM maize was heightened by the slowness of 
international organizations to come out and say that GM maize food aid was 
safe. In the absence of authoritative information, the debate over technical 
issues turned into sovereignty issues and become a fertile ground for anti-
GM activists to fuel the fears of policy makers and general public. The way 
forward is clearly a need for an open exchange of technical information 
about GM products, training African scientists, creating a public awareness 
of biotechnology issues, and helping African nations develop their own 
policies to guide regulatory, legal and technology transfer issues. 
 
This paper is divided into five parts. The first part discusses the problem. 
The second presents the rationale for using case studies to gain insight into 
the barriers to the development of GM crops in Africa. The third presents the 
results of seven cases studies and the challenge in developing biotech crops, 
getting them cleared by national biosafety committees and into the hands of 
smallholders in Africa. The fourth part draws lessons from the case studies. 
The fifth part discusses what financial resources, infrastructure and expertise 
(scientific, technical, political, institutional and financial) are needed to help 
Africa overcome these barriers and join the global biotech revolution. Since 
biotechnology is multidisciplinary, a comprehensive approach to capacity 
building should include capacity in science, regulatory, legal, ethical, 
communication, business management and entrepreneurship (Figure 1).  





                                                 
4 Johnson (2002) points out the difficulty of tracking grain movements from millions of farmers to consumers.   7
Figure 1. Comprehensive Approach to Embedding 
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II.  AGRICULTURAL BIOTECHNOLOGY 
 
Without question, getting agriculture moving is the central challenge for 
African political leaders and the donor community. But four decades ago, 
many agriculturalists were debating the same type of problem: what to do to 
solve Asia’s food crisis
5. Asia’s political leaders responded to the food crisis 
with massive investments in roads, irrigation and building research capacity. 
India, for example, built a chain of 33 state agricultural universities and sent 
1,000 agricultural scientists overseas for advanced training, as well as 
importing modern varieties of wheat and rice. India’s slow but steady 16-
year march from near famine in 1965 to food self-sufficiency in 1981 has 
many lessons for African nations today. India’s Green Revolution 
demonstrated that investment in agriculture was not only necessary, but also 
profitable, and that generating new knowledge through research could drive 
down the real cost of food production and indirectly combat poverty through 
lower food prices.  
 
Doubling aid to Africa is now being promoted as a strategy to “buy” rapid 
development.  Jeffrey Sachs (2005) and the recent Blair report (Commission 
for Africa 2005) both call for a doubling of aid to Africa. But there is 
abundant evidence that-aid by itself cannot buy development. The political 
commitment to get agriculture moving must start in State Houses across 
Africa.  
 
In addressing the role of agricultural biotechnology in African development, 
we begin with a discussion of population growth and then consider estimates 
of the rate of growth of food and livestock production over the coming 25 
years. Although global population growth has slowed, the FAO estimates 
that Africa’s projected annual rate of population growth of 2.8 percent will 
lead to a doubling of the size of Africa’s population in 25 years (FAO 2005). 
This leads to the question: How will Ethiopia feed 120 to 140 million people 
in 2030? 
 
Looking ahead to future sources of food production and agricultural growth, 
the overarching challenge in African agriculture is to lift the cereal yield 
ceiling which has been flat in Africa since the 1960s (Figure 2).  
                                                 
5 For a discussion of major issues in Asian agricultural development in the 1960s, see Eicher and Witt (1964); 
Mellor(1976); and Lele and Goldsmith (1989).   9
Source: World Bank 2005. 
 
This poses the question: can agricultural extension agents or conventional 
plant breeding or biotechnology-driven crop improvement lift cereal yields? 
There is abundant evidence that an army of extension workers, NGOs and 
Peace Corps Volunteers have been unable to develop high yielding crop 
varieties and bring Green Revolutions to Africa. Although extension 
workers and NGOs can play a useful role in speeding up the adoption of 
improved agricultural, health and nutrition practices, the bottom line is that 
long-term investments in research are needed to develop high yielding crop 
varieties and improved crop and livestock practices for smallholders (Gemo, 
Eicher and Teclemariam 2005). And because of the risk and time involved, 
most of the needed investments in agricultural research will have to be 
financed by African governments – not the private sector.  Since increasing 
cereal yields is the agricultural challenge facing Africa, this raises a key 
question: what priority should be given to future investments in plant 
breeding and in GM crops?
6   
 
Donors joined the biotechnology race in the early nineties amid a spirit of 
optimism and dreams of agricultural biotechnology producing quick success 
                                                 
6 Biotechnology is an outgrowth of a U.S. ruling in 1980 that microorganism could be patented under existing law and 
a l985 ruling that patent protection could be extended to genetically engineered plants. These critical events sparked a 
surge in private, public and university investments in medical biotechnology research and later in agricultural 
biotechnology. 
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and impact. This optimism was captured in the title of the report of the 
World Bank   Agricultural Biotechnology –“The Next Green Revolution”? 
(1991). Today, the Gene Revolution is divided into two camps. Proponents 
include Ndiritu (2000), Borlaug (2000), Chetsanga (2002), Wambugu (2001) 
Persley and Lantin (2000), Thomson (2002), Sithole-Niang (2005) 
DeGregori (2001) and many others. These proponents are reinforced by Bt 
impact assessments by Huang and Wang (2003) and Qaim and Matuschke 
(forthcoming) that have contributed to the optimistic view of agricultural 
biotechnology in developing countries.  The unabashed leader of the 
optimistic view of the potential of biotech crops is Nobel Laureate Norman 
Borlaug who describes anti-GM critics as engaged in “hysteria” and “in need 
of a better education in biological science” (2003). Without question, there is 
skepticism in Europe about GM food.
7 
 
The critics of biotech crops include Altieri (2001), Greenpeace, Oxfam, 
Global Justice Ecology Project, Vandana Shiva, GRAIN (2004) and many 
African governments.” Critics emphasize the potential health and 
environmental risks and the dominance of multi-national corporations in 
research and development decision making in developing countries. 
However, the unexpected environmental benefits of Bt cotton are helping 
some African policy makers change their position on GM crops and food 
aid. Because of the favorable health effects of reduced spraying of cotton, it 
is clear that reducing pesticide use and protecting the health of cotton 
farmers are important rejoinders to the anti-GM critics (Maumbe and 
Swinton 2003). 
 
Today, the facts paint an optimistic picture of the growth of biotech crops. In 
2004, the global area of biotech crops grew by 20 percent (James 2004). 
Eight million farmers in 17 countries grew biotech crops in 2004. South 
Africa is the eighth largest country in the world in terms of biotech crops 
(maize and cotton) grown commercially. Despite the outpouring of global 
literature on GM crops, there is a dearth of information on the long and 
arduous process of developing GM commodities and biosafety regulations.
8 
                                                 
7 For more information on GMOs in Europe see Questions and Answers on the Regulations of GMOs in the European 
Union May 20, 2005. http://europa.eu.int/comm/food/food/biotechnology/gmfood/qanda_en.htm. Tollens (2002) 
reports that the Government of Flanders founded VIB, an autonomous biotech research institution in Belgium in 1995. 
VIB has 750 researchers and technicians engaged in biotech research. 
8 For example, Zambia’s decision in 2002 to reject GM food aid from the United States even as the country was facing 
drought was followed by intense debate over whether the food aid was GM grain and whether it contained possible 
health, environment and trade concerns. Recently, the Zambian government developed a National Biosafety and 
Biotechnology Strategy Plan (Zambia 2005), which aim to build biosafety capability and ensure GM crops are 
appropriately regulated. Zambia is now facing is third drought since 2000 and it now needs 200,000 tons of maize to   11
The results of our analysis of seven commodities (six food crops and one 
export crop-cotton) will shed light on the role of the technical, managerial, 
financial and institutional factors that shape the scientific discovery process 
and the development of biosafety regulatory frameworks in Africa (Sithole-
Niang et al 2004). 
 
The case studies will show that GM crops are facing an unexpected set of 
scientific and regulatory issues and even if these are resolved the rise and 
decline of smallholder Bt cotton in South Africa shows that sustainable 
adoption of Bt crops requires a number of institutional problems to be solved 
such as seed and fertilizer input systems, access to markets and favorable 
economic and trade policies. These are the same problems that constrained 
the adoption of hybrid maize in Eastern and Southern Africa in the 1970s 
and 1980s (Byerlee and Eicher 1997). 
 
 
III. AFRICA’S EXPERIENCE IN DEVELOPING GM CROPS: 
SEVEN CASE STUDIES 
Introduction  
Tissue culture research, the first stage of biotechnology research, was 
launched in several CGIAR centers in the late seventies followed by the 
governments of South Africa and China in the mid 1980s. In the late 
eighties, Kenya developed tissue culture capacity to reinvigorate its 
pyrethrum research program.
9 Many other countries in Eastern Africa have 
developed impressive tissue culture facilities.   
 
Since donors are discussing various proposals to increase aid to African 
agriculture, it is an appropriate time to step back and analyze investment 
priorities in plant breeding verses GM crop development in Africa. First we 
start with conceptual issues in understanding the pathway of biotech crop 
development. Ruttan (1999) has developed a simple three-stage 
classification of the goals of agricultural biotechnology development starting 
with stage I where the goal is lifting the yield ceiling of cereals (Figure 2). 
                                                                                                                                                 
avert a crisis in 2005. But Zambia has reaffirmed its ban on GM products until it is satisfied they pose no threat to 
health or the environment. Food aid fears surfaced in Angola in December 2004 and the government now requires 
food-aid grain to be milled before it is distributed. Namibia cut off all corn trade with South Africa in 2004 because the 
latter grows GM corn. 
9 Florence Wambugu (2001) describes tissue culture “ as a relatively simple and inexpensive set of technologies that 
allows whole plants to be propagated from minute amounts of plant tissue even just a single cell of the plant.”  Tissue 
culture represents a necessary first step in building and managing a varietal improvement system that is linked to seed 
distribution and upstream biotechnology (Lynam 1995).   12
The second stage focuses on enhancing the nutritive value of cereals such as 
golden rice, which increases the Vitamin A intake, and reduces child 
blindness. The third stage focuses on the development of plants as nutrient 
factories to supply food, feed and fiber.  
Byerlee and Fischer (2002) have laid out a three-stage model of the process 
of developing and diffusing biotechnology. Type I countries are weak NARS 
(National Agricultural Research Systems) using tissue culture and have little 
private sector activity. Type II countries have medium to strong NARS with 
strong national commodity research programs and have some capacity in 
molecular biology. Type III countries have very strong NARS with 
considerable research on transgenics. 
FAO's State of Food and Agriculture 2003/2004 includes a valuable global 
assessment of agricultural biotechnology. The FAO (2004) urges caution in 
drawing “strong conclusions” from surveys because the crops have often 
been grown for only a few years and the sample size of farmers may be 
small. The discussion of smallholder GM cotton in South Africa below is a 
sobering reminder of the risks involved in speculating on future adoption 
rates. 
What can Africa learn from the global GM experience to date? Cohen and 
Paarlberg (2004) recently surveyed six developing countries (including 
Kenya) and concluded that biosafety procedures for GM crops were not 
working well. They report that it is difficult to make and enforce regulatory 
decisions because decisions must be applied at three points: approval for 
confined trials; approval for larger location trials, and finally approval for 
commercial use.  
More recently, Cohen (2005) teamed up with researchers on three continents 
and studied the role of the public sector in the transformation process in 15 
developing countries and concluded, "The public sector is a competent but 
largely unproven player for GM leadership in developing countries.”
10 One 
of the surprising findings of the 15-nation survey was the high cost of 
compliance for the regulatory approval of a single transformation event, 
ranging from US$ 700,000 for virus-resistance papaya to US $4 million for 
herbicide- resistant soybeans. These global insights point out the barriers and 
time lags in gaining biosafety regulatory approval, the high cost of 
compliance for regulatory approval and the growing number of ex ante 
                                                 
10 See also Sithole-Niang et. al. 2004)   13
studies showing favorable results of GM crops for farmers, consumers and 
the environment.  
 
The results of the following seven case studies will help answer two central 
questions. First, what are the barriers that have delayed the development and 
biosafety regulatory approval for testing and release of biotech crops in 
Africa? Second, what are the challenges and priorities in building public 
awareness of biotechnology and biosafety and the African scientific 
technical, legal and managerial capacity to develop, test and diffuse GM 
crop technology to smallholder farmers in Africa? 
   14
1. Insect and Virus Resistant Sweet Potato 
 
Sweet potato, an important food staple grown in Kenya and other parts of 
the continent.
11 It is appealing to donors because it is predominately grown 
by resource-poor women farmers and it yields more food energy and 
micronutrients per hectare than any other crop (Qaim 2001). The sweet 
potato area under cultivation is expanding in Kenya because of rapid 
population growth. But sweet potato yields have declined in recent years 
because of virus diseases; the average sweet potato yield in Kenya is around 
6 ton/ha as compared with 18 ton/ha in China. 
 
Transgenic sweet potato research is designed to develop varieties that are 
resistant to potato weevils and virus diseases, especially the sweet potato 
feathery mottle virus. In 1991, the Monsanto Company offered to transfer a 
virus resistant GM sweet potato from the United States to KARI (Kenya 
Agricultural Research Institute) on a royalty-free basis as a means of   
improving the food security of Kenya.
12   
 
During the early nineties, a variety of Kenyan organizations and donors 
pulled KARI’s evolving biotech program in many different directions. The 
development of national biosafety regulations is a case in point. In 1996, 
five years after Monsanto’s offer to transfer a virus resistant sweet potato to 
Kenya, the government of Kenya formed a National Biosafety Committee 
(NBC) under the National Council of Science and Technology. Two years 
later, the NBC published a set of Regulations and Guidelines for Biosafety 
in Kenya (Cohen and Paarlberg 2004). The fact that it took seven years 
(1991-1998) to set up a biosafety committee and develop and publish 
national biosafety guidelines, illustrates how time passes when the drafting 
process is supported by a variety of donors without proper coordination of 
various activities and projects.   
 
Since some of the basic research functions in crossing Kenya sweet potatoes 
with the Monsanto lines were to be performed in Monsanto laboratories in 
the United States, Kenyan scientists were invited to the United States to 
carry out the experiments in cooperation with Monsanto scientists 
(Wambugu 1999). However, technical problems were encountered in 
                                                 
11 This case study draws on Wambugu (1999,2001); Wambugu and Kiome 2001; Odame et al (2002); Qaim 
(1999,2001); Qaim and Matusche 2004; Wafulu  et al (2004); Paarlberg (2001) and Cohen and Paarlberg (2004). 
12 Kenya would then be able to pass on the GM sweet potatoes to any other African country on a royalty –free basis.   15
transforming Kenyan cultivars that were taken to the United States to be 
transformed and a sweet potato variety from Papua New Guinea had to be 
used at Monsanto in place of a Kenyan material (Paarlberg 2001).)  
 
In 1998, KARI requested its National Biosafety Committee (NBC) to allow 
it to import its GM sweet potato materials from Monsanto in the United 
States into Kenya. However, it took the NBC two years to approve the 
importation of the material and field trials of transgenic sweet potatoes have 
been ongoing since 2001. A total of four seasons of trials and final NBC 
approval will be needed before release to smallholders. It now appears that 
some basic science and research priority issues are hanging over the sweet 
potato experiment.
13 Some scientists believe that the construct for virus 
resistance was not well tested and it did not hold up in the field trials. One 
might question whether there was a need to link biotech research with a 
well-developed conventional breeding program The International Potato 
Center (CIP) and Auburn University in the United States are now working 
on a transgenic approach to weevil protection, but researchers are still far 
away from a product to release to farmers. To summarize the transgenic 
sweet potato is still making its way through the regulatory approval process 
in Kenya.  
 
2. Insect Resistant Bt Potato 
 
This case study is a progress report of an ongoing collaborative research 
program to develop and commercialize Bt Potatoes to control Potato Tuber 
Moth in Egypt and South Africa. The potato (Solanum tuberosum L.) is an 
important food crop in Africa.  The Potato Tuber Moth (PTM) (Phthorimaea 
operculella Zeller) is a serious pest of potato in Egypt, South Africa, 
Ethiopia, and other countries in Africa. The tuber moth mines leaves and 
feeds on tubers in the field and in storage.  Losses of up to 100 percent have 
been reported in storage.  
 
Michigan State University (MSU) has maintained a conventional breeding 
program for potato improvement for many decades and biotechnology has 
been integrated into the breeding program to address insects, pests, disease 
and other constraints. In 1993, the MSU potato team
14 secured funding from 
                                                 
13 Two years ago KARI sub licensed the virus resistance technology to the Danforth Center (USA). 
14 The Bt potato research team at Michigan State University includes Johan Brink, David Douches, Walter Pett, Edward Grafius, 
Karim Maredia, Hector Quemada. South African researchers include Muffy Koch, Kobie de Rone, Diedrich Visser and Ben 
Pieterse.   16
the USAID mission in Cairo to form a partnership with the Agricultural 
Genetic Engineering Research Institute (AGERI) in Egypt. The goal was to 
develop transgenic Bt potatoes with PTM resistance and reduce the losses 
from PTM and the use of pesticides.  The Egypt project started as a 
collaborative program under the Agricultural Biotechnology Support Project 
(ABSP) that was managed by MSU and funded by USAID.  The ABSP 
Project licensed the codon-modified cry1Ia1Bt gene from the ICI Seeds 
Company in October 1994.  This gene was licensed for research purposes to 
develop transgenic potatoes resistance to PTM.  MSU currently has a license 
to use this gene in potato research.   
 
The MSU potato team in collaboration with the AGERI scientists in Egypt 
developed Bt potato lines using the cry1Ia1 gene.  The potato variety 
“Spunta” was one of many lines or varieties transformed by using this gene.  
The Spunta is a Dutch variety that has been widely grown in Egypt for local 
markets.  The transgenic Bt potato lines were transferred to Egypt under a 
material transfer agreement (MTA) and field-tested at two locations from 
1997 – 2001.   The Bt Spunta lines performed well in Egypt and provided 
excellent control of PTM both in the field and storage.  However, Egypt 
regularly exports potatoes and other agricultural commodities to the 
European Union (EU).  After eight years of potato research in Egypt, the 
government decided not to commercialize the Bt potatoes at this time 
because of trade concerns with the EU over GMs crops.  Even though the Bt 
potatoes have not been commercialized in Egypt, the project helped build 
biotechnology research and policy capacity in Egypt over the 1993 – 2001 
period. 
 
The MSU potato research team turned to South Africa in 2001 and 
developed a joint research project with the Agricultural Research Council 
(ARC) with an initial goal to commercialize PTM resistant Bt potatoes for 
resource-poor farmers.  The Spunta Bt potato lines were transferred to the 
ARC’s Vegetable and Ornamental Plant Institute (VOPI) in Roodeplaat 
under a material transfer agreement for a field trial in South Africa. VOPI 
has excellent infrastructure and a national potato-breeding program.    The 
first field trial was conducted at VOPI in 2001 and repeated in 2002 and 
2003 at two locations. In 2004, field trials were planted at five locations.  
The field and storage trials in South Africa have produced excellent results 
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in terms of PTM control and have generated interest among both resource-
poor and commercial farmers in growing the Bt variety. 
 
As a result of corporate mergers and acquisitions, the ownership of cry1Ia1 
Bt gene now resides with the Syngenta Company.  In addition, the Spunta Bt 
potato lines contain intellectual properties that are owned by the Monsanto 
Company (promoter and a marker gene).  The MSU Technology Transfer 
team has started negotiations with Syngenta to obtain a license to 
commercialize the Spunta G2 Bt line in South Africa.  Syngenta is willing to 
grant the license but it has requested a full regulatory approval of the South 
Africa government before granting a commercial license.  The company is 
also concerned about the liability and stewardship issues, specially the 
potential trans-boundary movement of Bt potatoes into neighboring 
countries that do not have biosafety regulatory policies and regimes/systems 
in place.  The MSU technology transfer team has also initiated discussions 
with Monsanto because it owns two of the intellectual properties used in this 
project (promoter and marker gene). Hence there is a need for a regional 
regulatory framework. 
 
The MSU team is also developing a regulatory file to submit to the South 
African government.  As a part of this effort, MSU and VOPI are gathering 
environmental biosafety, food safety and toxicology data in collaboration 
with local and international experts.  A South African Team is also 
conducting an ex-ante socio-economic assessment.   
 
The MSU potato team, in collaboration with VOPI scientists, is currently 
transforming three additional potato varieties that are important to 
smallholder and commercial farmers in South Africa (BP1, Mnandi and 
Darius). VOPI, Potatoes South Africa, and local companies are discussing 
the development of a road map for seed production, commercialization and 
distribution of this technology to farmers in South Africa. It is expected that 
it will take at least three to four more years to commercialize this technology 
in South Africa, provided a commercial license and regulatory approvals are 
granted for this technology. The expected outcome of the application of Bt 
technology in potato in South Africa will be to reduce the losses from PTM 
damage in the field and in storage and reduce the use of chemical pesticides.  
The project has enhanced biotechnology and management capacity in South 
Africa and it can serve as an excellent technology bridge to other countries 
in southern Africa. 
   18
In summary, two major barriers to commercialization have emerged for the 
same crop in two countries on the same continent.  First, Egypt fears the loss 
of its potato export market to Europe if the Bt technology is commercialized. 
Second, in South Africa, progress has been delayed because of the 
unexpected liability issues arising from the potential cross-boundary 
movement of Bt potatoes from South Africa to neighboring countries that do 
not have functional biosafety policies and regulatory regimes/systems or 
where the Bt technology is not registered.  Brenner (2004) recently reviewed 
the potato project and concluded “Bt potato lines have been field-tested in 
Michigan, Egypt, and South Africa over the life of the ABSP project. Not 
only have they performed well agronomically, they have also expressed 
excellent resistance to PTM both in the field and in storage.” However, the 
Spunta G2 Bt transgenic potato variety is still not grown by the smallholders 
in Africa despite 12 years of research and more than $3 million of donor 
funding for the Potato Tuber Moth project (1993 – 2005). The projected time 
of GM release to farmers is around four years. 
   19
3. Insect Resistant Bt Maize 
 
It is predicted that by 2020, maize will surpass both wheat and rice as the 
number one cereal in the world. Developing countries plant two thirds of the 
global maize production while industrialized countries plant one third.  Nine 
of the top 25 maize-producing countries are from Africa. Globally, maize is 
severely constrained by insect pests. Half of these losses are due to 
lepidopteran insects that can be controlled by the Bt toxin Protein gene. 
Other production constraints include drought, low N, soil acidity, insect 
pests, infestation by parasitic weeds (Striga sp.), viral and  fungal diseases. 
 
The International Maize and Wheat Improvement Center (CIMMYT) and 
the International Institute for Tropical Agriculture (IITA) have the CGIAR 
mandate for maize improvement in Africa, with the former being responsible 
for eastern, central and southern Africa and the latter for West Africa.  
Drought tolerance, nitrogen use efficiency, Striga tolerance, stemborer and 
post harvest pest resistance, several leaf and grain diseases, and grain quality 
characteristics are priority traits for improvement.  
 
To date several GM products that have been developed (De Villiers and 
Ferguson, 2004) by the private and public sectors. The Universities of Cape 
Town and KwaZulu Natal in South Africa are developing new products in 
drought tolerance.  Maize engineered for drought tolerance using an 
antioxidant gene from the resurrection plant, Xerophyta viscose, has been 
transferred to the African Center for Crop Improvement (ACCI) of the 
University of KwaZulu Natal for further evaluation.   The University of 
Cape Town is also developing a maize streak virus resistant maize line 
which, if found effective, will be back crossed into locally preferred and 
adaptable germplasm.  This development fits in nicely with existing policy 
developments in South Africa, where GM maize, both yellow and white 
maize varieties have been commercialized.  South Africa is the first country 
in the world to commercialize a GM crop that is also a staple food, white 
maize (Gouse et al., 2005).   
 
In collaboration with CIMMYT, the Kenya Agriculture Research Institute 
(KARI) embarked in 1999 on the development of insect resistant transgenic 
maize in a project popularly known as Insect Resistant Maize for Africa 
(IRMA).  The maize was transformed with cry1Ab and cry2A and 
backcrossed into African-adapted varieties in Mexico. Leaf assays were 
conducted in Kenya followed by trials in a newly established biosafety level   20
2 greenhouse facility and confined field trials.  IRMA Phase 2 aims at 
distributing two types of maize, one developed through conventional means 
and the other by genetic engineering using Bt- technology.   The 
conventionally bred material that uses leaf toughness as the main attribute to 
insect tolerance is currently undergoing performance trials within the 
national program.  The transgenic plants are devoid of marker genes, and 
continue to be backcrossed into Kenya varieties. Impact assessments gene 
flow, socio-economic and base line studies have already been conducted 
(Mugo et al., 2005). On May 27, 2005 the government of Kenya planted 
confined field trials of Bt maize.
15 It is estimated that it will take another 
four or five years of field trials before the GM maize can be approved and 
released to farmers. The IRMA project will ensure that smallholders in sub-
Saharan Africa have access to maize resistant to stem borers. The Syngenta 
and Rockefeller Foundations are providing funding.   
 
In April 2005 a biosafety level 2 Facility for Plant Genetic Transformation 
was established at Kenyatta University in Kenya.  The Facility will be used 
primarily for maize genetic transformation to generate maize that is 
resistance to Striga as well as drought tolerant varieties.  This facility will 
train students from Kenya, Ethiopia, Sudan, and Tanzania at masters and 
doctoral levels. The Kenyatta University researchers are working closely 
with the private sector as well as donors, notably the Rockefeller 
Foundation, USAID, and the USDA.   
 
4. Insect Resistant Bt Cotton 
 
Cotton is the second most important global GM crop (after soybeans) in 
terms of area planted. African policy makers are well aware of the expansion 
of smallholder cotton production in China,
16 South Africa and more recently, 
in India. Spurred by these success stories, Bt cotton field trials are now 
underway in Tanzania and Burkina Faso and Mali will soon initiate testing. 
                                                 
15 See http://www.cimmyt.org/english/wps/news/2005/may/kenyaTransgenic.htm 
16 Bt cotton in China is the global GM success story in developing countries (Huang and Wang 2003). Cotton is an 
important source of income for smallholders and also an important export crop. Biotechnology research began in the 
mid eighties with large public investments and the Chinese Academy of Agricultural Sciences secured patents, plant 
varieties, trademark protection and developed Bt cotton. The original 22 transgenic lines were sublicensed to provincial 
seed companies, which backcrossed the trans genes into well-adapted local varieties to ensure that appropriate local Bt 
varieties would be available to smallholders throughout the country (Conway, Toenniessen and de Vries 2003; Pray et 
al 2002 and Shirong et al 2004).  
The Chinese experience demonstrates the payoff to staying the course and sustaining the commitment of public 
investments in Bt cotton research for over two decades. The Chinese experience also sends a political message to 
policy makers in Africa.  Huang and Wang (2003) report,  “Chinese policymakers consider agricultural biotechnology 
as a strategically significant tool for improving national food security, raising agricultural productivity and creating a 
competitive position in international agricultural markets”.    21
The anti-GM critics have a hard time criticizing GM cotton because it 
requires substantially less pesticides than conventional cotton varieties, 
produces higher yields and incomes for poor farmers and is better for the 
health of smallholders by reducing the number of insecticide sprays. The 
major fear associated with the use of Bt cotton is the possibility that pests 
may develop a resistance to it as they have done with chemical pesticides. 
Currently, another international policy issue surrounding cotton are the 
subsidies being paid to farmers producing cotton in industrial counties.
17 
 
What is Bt cotton?  The genes from the common soil bacterium Bacillus 
thuringiensis (Bt) can be inserted into the cotton plants to produce a protein 
that is toxic to caterpillar pests such as the pink bollworm and cotton 
bollworm (Traxler et al 2004). In 1996, the first Bt cotton varieties were 
introduced commercially in the United States, Mexico and Australia through 
a licensing agreement between Monsanto, the gene discoverer, and Delta 
and Pine Land, an international seed company. The Delta seeds are sold 
under the trade name Bollgard®. Farmers wanting to use Bollgard® must 
pay for the seed and a technology fee. New Bollgard® seed must be planted 
every year according to the company’s agreement with the growers. 
 
In examining the reasons for the rapid growth of transgenic cotton, we begin 
with South Africa because it is the African leader in terms of developing 
public sector biotech research capacity and it has both large scale and 
smallholders producing GM crops.  
 
South Africa 
South Africa is the pacesetter for GM research and GM crop production in 
Africa. Cotton is grown by smallholders on rainfed land and by large-scale 
farms on irrigated land. Smallholders generally have 1-3 hectare farms and 
plant about one half hectare to rainfed cotton. Bt cotton was commercially 
introduced in the Makhatini Flats in the Kwa-Zulu Natal region in 1999 
(Kirsten and Gouse 2003). Two years later, around 90 percent of the 3500 
smallholders had adopted Bt cotton (Gouse et al.. 2003). The early adopters 
of the Bt varieties reported higher incomes because of the reduced cost of 
pesticides and slightly higher yields.  Thirtle et al.. (2003) found that higher 
yields and lower chemical costs outweighed seed costs, giving higher gross 
margins to adopters.  
                                                 
17 See Minot and Daniels (forthcoming) for a study of the impact of cotton subsidies on cotton production in Benin.   22
 
However, in 2002/2003, “things started to fall apart” when a new cotton 
company installed a gin next to the original gin that had provided credit to 
smallholders growing cotton since the inception of the project in 1999. 
Unfortunately, some of the smallholders sold their cotton to the new gin and 
the original gin lost money and discontinued the provision of credit to 
smallholders. As a result, over the past two years, cotton production has 
been drastically reduced due to a lack of credit, declining world cotton prices 
and drought (Gouse 2005). Several researchers recently concluded that 
smallholder Bt cotton in the KwaZula Natal represents a “technological 
triumph but an institutional failure” (Gouse et al 2005).
18 The South African 
experience adds evidence to the proposition that “institutions matter” (Eicher 
1999) and that research is urgently needed on what Tripp (2003) has called 
the “enabling environment”, including how to develop efficient input 
markets to facilitate the adoption of biotech crops.
 19 But keep in mind that 
developing efficient input markets is one of the oldest and toughest 
institutional problems to be solved in African agriculture. 
Tanzania 
Tanzania’s smallholder cotton experience in the Mbeya, Rukwa and Iringa 
regions in the 1960s illustrates the devastating impact of insects on cotton. In 
fact, the bollworm attack was so severe in 1968 that the government ordered 
farmers to stop growing cotton in the three regions because of the fear that it 
would spread to the entire country (Balile 2005). Recently, Tanzania took a 
political decision to increase its domestic budget for strengthening its 
science capacity and in April 2005, Tanzania became the seventh African 
country to launch field trials of Bt cotton. Researchers at Sokoine University 
of Agriculture will supervise the government-managed trials. Tanzania’s 
Ministry of Agriculture recently reported, “Tanzania cannot afford to be left 
behind by technologies that increase yields, reduce farm costs and increase 
profits” (Balile 2005).  
 
West Africa 
Cotton is one of the most important agricultural exports for many countries 
in West Africa.
20 In Burkina Faso, cotton is the lifeblood of 2.5 million 
farmers. Burkina’s national agricultural research organization - INERA - and 
Monsanto signed a partnership agreement and launched field trials of Bt 
                                                 
18 Gouse (2005) points out that smallholders  lost their access to credit because the two cotton gins could not co-exist 
nor cooperate. This failure has been exacerbated by the low world price of cotton and drought. 
19 See Kherralah et al (2002) and Kelly, Adesina and Gordon (2003) for a discussion of the difficulties in reforming 
agricultural markets in Africa.   23
cotton in 2003/2004. The trials reduced Bollworms by 92 percent and 
increased yields by 15 to 20 percent (Greenplate 2004).  
Summary of Bt Cotton 
 
The commercialization of biotech crops is now a decade old. The adoption 
of smallholder Bt cotton in China and India has reduced the use of 
pesticides, and increased yields and farm incomes. The expansion of Bt 
cotton has captured the attention of many African policy makers and has 
stimulated GM cotton trials in Africa. But the recent rise and decline in 
smallholder production of Bt cotton in South Africa because of credit 
problems, drought and low world prices illustrates the urgent need for 
research on seed marketing reforms and a number of complex institutional 
and capacity-building issues. 
 
5. Disease and Insect Resistant Banana 
 
The East African highland banana is an important food and cash crop for 
many resource poor smallholders in Eastern and Central Africa, including 
Uganda, Kenya, Tanzania, and Rwanda. In Uganda, more than one third of 
the cultivated land is planted to banana and per capita consumption is the 
highest in the world, estimated at 250 kg per capita/year or, roughly .70 kg 
per person per day (ASBP II 2004). Most bananas are locally consumed as 
cooking or beer bananas. The East African highland banana is susceptible to 
pests (nematodes, banana weevils) and diseases (Black Sigatoka, Banana 
Streak virus, Bacterial wilt), and host resistance was identified as one of the 
most feasible alternatives to control the pest and disease problem.  The 
national banana research programme adopted both short term and long term 
approaches to address this problem.  The short term approach included 
assembling of local and foreign germplasm for evaluation and selection of 
resistant or tolerant cultivars, propagation of superior, clean planting 
materials through tissue culture, and importation of hybrids from other 
breeding centers including Foundacion Hondurena De Investigacion 
Agricola (FHIA) and the International Institute of Tropical Agriculture 
(IITA), Ibadan-Nigeria for evaluation against local pests and diseases.  The 
long term strategy includes breeding for resistance with genetic 
transformation. (Kikulwe et al. 2005). 
 
                                                                                                                                                 
20 See Alassan 2003.   24
Since 2000, the government of Uganda has annually contributed funds to the 
International Network for the Improvement of Banana (INIBAP) to carry out 
research on the major banana diseases in cooperation with Uganda’s 
National Agricultural Research Organization (NARO), the KUL, CIRAD, 
IITA, the University of Pretoria and other institutions such as Leeds 
University on an informal basis. The goal of the joint project is to contribute 
to food and income security of smallholders in Uganda through improved 
banana production by introducing genes, which result in enhanced tolerance 
to Black Sigatoka and nematodes using genetic transformation technologies. 
In 2003, a new biotechnology laboratory for genetically modifying bananas 
was opened at the National Agricultural Research Organization (NARO). 
KUL, in Belgium, houses the world’s largest collection of banana and 
germplasm is sent around the world as tissue culture material. The goal of 
the NARO/KUL partnership is to insert genes into bananas that will enhance 
resistance to Black Sigtoka and banana weevils. NARO scientists have 
identified several varieties for initial transformation assays in order to 
represent the range of genomic and use group diversity found among clone 
sets in Uganda (Karamura, and Karamura 1994). Edmeades and Smale 
(2005) demonstrate the pro-poor potential of transgenic East African 
highland cooking bananas and predict the sensitivity of farmer demand for 
transgenic planting material to research and other investments.
21  
 
Looking ahead, what is the time-line for getting transgenic bananas into the 
hands of smallholders in Uganda? A recent assessment of on-going 
transgenic research for solving major pest and disease problems (fungal, 
nematode, bacterial, weevil, and viral) concluded that, in the medium- term, 
the approach that is most likely to deliver improved transgenic material to 
smallholder farmers will take seven to ten years of further technology 
development, and building NARO’s capacity in biosafety for contained and 
ultimately field trials of transgenic plants (Quemada and Johanson 2004).  
 
To summarize, the development and use of tissue culture in banana research 
is an important achievement. However, transgenic research has been slow in 
combating Black Sigatoka and banana weevil because of many complex 
scientific and biosafety issues. More time is needed to deliver transgenic 
bananas to smallholder farmers in Uganda. 
 
                                                 
21 The problems encountered with the recent introduction of banana hybrids illustrated the need for research by social 
scientists on locally important variety attributes from a consumer’s perspective. Although the banana hybrids have 
large bunches, consumers report they are inferior in terms of cooking quality.   25
6. Insect Resistant Bt Cowpea 
Cowpea is a low cost vegetable protein generally grown by women.  The 
crop is consumed as fresh green leaves, soft pod, as well as dry grain. The 
crop is a rich source of vegetable protein. The stover of cowpea is used as 
fodder, especially during the dry season. Cowpea is drought tolerant and it 
can be used to enrich the soil through nitrogen fixation. But cowpea suffers 
from severe insect pest and disease pressure during vegetative growth and 
the cowpea weevil during post harvest storage (De Villiers and Ferguson, 
2004).   Production constraints include: insect pests, storage weevils, fungal 
diseases, bacterial blight, viruses and the parasitic weed Striga gesneroides. 
The IITA has been breeding cowpea for years, while scientists in the USAID 
funded Bean Cowpea Collaborative Research Support Program (B/C CRSP) 
have been breeding cowpea varieties for West African ecologies for two 
decades. Some success has been achieved for breeding against bacterial, 
fungal and viral diseases, but unfortunately, not much success has been 
achieved for insect pests (Singh, 2004).   
 
The Network for the Genetic Improvement of Cowpea for Africa (NGICA) 
was established in 2001 to focus research attention on cowpea, an “orphan” 
crop in terms of attracting research funding. Larry Murdock of Purdue 
University, and Idah Sithole-Niang of the University of Zimbabwe, Harare, 
manage the network. In 2001, Murdock convened a meeting of cowpea 
researchers in Dakar to assess the state-of-the-art of cowpea research and 
devise plans and new research initiatives to address constraints on cowpea 
production and storage in Africa. The assembled researchers concluded that 
pests were by far the largest single challenge the crop faced and that Maruca 
vitrata was the most damaging. The researchers also concluded that genetic 
engineering tools might be useful in reducing smallholder losses from pests 
in the field and in storage. 
 
The Dakar meeting launched the NGICA and the membership was drawn 
from the scientists, administrators, business people, non-governmental 
organizations (NGOs) and individuals committed to the genetic 
improvement of cowpea.  The group decided that resource poor farmers in 
Africa should be the ultimate beneficiaries and a coordinated international 
effort was needed to introduce new traits into the cowpea by using marker-
assisted breeding, genetic mapping and molecular genetic transformation.  
The group also decided that new tools of biotechnology and genetic 
engineering should be integrated into traditional breeding programs,   26
regulatory constraints should be addressed and a Steering Committee was 
needed to coordinate the work of the Network. 
 
Murdock and Sithole-Niang urged donors to continue funding the following 
cowpea research groups:  
•  T.J. Higgins group, CSIRO, Australia, 
•  George Bruening, UC/Davis and Ivan Inglebrecht, IITA 
•  Ray Bressan, Purdue University 
•  Richard Allison, Michigan State University & Idah Sithole-Niang, 
University of Zimbabwe 
 
The research groups also met with the private sector and discussed the 
acquisition of proprietary technology, namely the Bt gene. These discussions 
reached an advanced stage, but when the African Agricultural Technology 
Foundation (AATF) was formed, it included the Cowpea Productivity and 
Utilization project as one of the five pilot projects in its portfolio.
22  NGICA 
organized a meeting of Cowpea Molecular Biologists in Italy in 2002 to 
discuss the progress of the research groups and issues of ownership, 
recognition and technology transfer in the event that a particular research 
group succeeded in developing transgenic cowpea varieties.   
 
Pursuant to the 2004 Accra meeting, a joint proposal was sent to the Global 
Diversity Alliance (GDA) and funding was obtained to assist with the 
transformation effort.  Satisfied that enough effort was being devoted to 
genetic transformation, the Network turned to issues relating to marker-
assisted selection (MAS) because it was reasoned that if a Bt cowpea 
became available, the trait would need to be introgressed into locally 
adapted and preferred varieties. It was agreed that MAS would accelerate 
this process, and that discussions on MAS should begin immediately. The 
Kirkhouse Trust co-sponsored a second Cowpea Meeting in Accra in 
November. Discussions centered on specific technology transfer activities 
for both MAS and the genetic transformation of cowpea.  
 
In October 2004, the T.J. Higgins group introduced a foreign gene (the GUS 
marker gene) into cowpea cotyledonary nodes using Agrobacterium 
tumefaciens and identified 3 preferred cowpea lines, worked out the 
modalities of replicating the system, obtained fertile seeds, and had 
                                                 
22 The AATF plans to assist in cowpea research and utilization by launching a pilot AATF/NGICA project to address 
IP negotiations to access existing technologies, liability protection, license for distribution, Licensor/Licensee for 
cowpea network activities, and link producers, traders and consumers.   27
molecular data (Southern blots) to show that the gene was indeed in the 
plant/seed and could be passed on to the next generation.  Now Higgins’ 
group has to work on scale up and ensure that other people reproduced their 
experiments in different locales (Higgins, 2004). There is excitement among 
cowpea researchers and researchers who are now busy replicating the 
Higgins protocol in their laboratories.  
 
Murdock has developed a comprehensive flow chart spanning 14 years that 
outlines activities and tasks that had to be undertaken to develop a Bt 
cowpea.  The issues that emerged from the flow chart were: 
 
1.  Use of molecular tools was a small part of a much broader long-term 
research agenda 
2.  Some activities must be anticipated and initiated in a timely fashion 
3.  IPR issues must be addressed sooner 
4.  We must foster a community effort to succeed 
5.  Africans must be involved at all stages 
6.  Implementation and deployment of transgenic cowpea will first occur 
in a single African country, and that country was to be identified early 
7.  We must ensure sustainable deployment of transgenic cowpea 
8.  Genetic improvement must not be pursued in isolation, but must be 
viewed as part of the whole package 
 
The management of the NGICA has relied on donated time by key 
individuals.  The network per se has no legal status, thus limiting its ability 
to compete for technical, intellectual as well as budget support. Discussions 
are underway to formalize the network and select an individual to lead the 
cowpea research community.  The Secretariat will be located at an existing 
organization in Africa.  Lobbying, collaboration with key stakeholders and 
advocacy for cowpea in all areas, and capacity building will continue 
(Sithole-Niang and Murdock (2004).  There is close cooperation between 
NGICA, IITA and the Bean and Cowpea CRSP managed by Michigan State 
University.  
 
To summarize, the cowpea case study illustrates how difficult it is to 
mobilize donor support to carry out research on cowpea, an orphan crop. 
This suggests that the first step in resource mobilization is to seek support 
from African governments to finance targeted research on orphan crops. The 
insect resistant GM cowpea varieties developed through biotechnology are 
many years away from release to smallholder farmers in Africa.   28
7. Virus Resistant Cassava 
 
Cassava is the second most important food crop in Africa and it has 
unrealized potential for industrial exploitation.
23 Cassava Mosaic Disease 
(CMD), a viral disease transmitted by white flies and vegetative propagation 
destroys one-third of the harvest each year.  Scientists at the Donald 
Danforth Plant Science Center (USA) have succeeded in introducing a gene 
into cassava through genetic engineering that imparts resistance to the 
viruses that cause CMD.
24 These viruses include the African cassava mosaic 
virus (ACMV) and the East African cassava mosaic virus (EACMV). Three 
seasons of testing these transgenic plants in greenhouses in the United States 
have demonstrated high levels of resistance to CMD.  Given these promising 
greenhouse results, the Danforth scientists decided to test the plants in the 
field where the disease pressure is high. Kenya was selected as the priority 
site for this trial because (a) it permits field trials of GM crops, and (b) CMD 
is a severe problem. In April 2003, USAID/Washington made a one-year 
grant to the Danforth Center to prepare for a field trial in Kenya.  The 
Danforth Center signed a MoU with the Kenyan Agricultural Research 
Institute (KARI).  The Danforth Center and KARI are in the process of 
obtaining regulatory approval for conducting a field trial in Kenya. KARI 
and Danforth Center have jointly identified local cultivars for 
transformation.   
 
In the fall of 2003, USAID awarded a one-year grant to the Danforth Center 
to try to initiate Nigeria’s first field trial of a GM crop. The Danforth Center 
along with the International Institute for Tropical Agriculture (IITA), the 
National Biotechnology Development Agency (NABDA) and the National 
Root Crops Research Institute (NRCRI) have designed a field trial and 
completed the biosafety dossier/application required by the Nigerian 
government. The application has been reviewed and approved by the 
biosafety committees at IITA and NRCRI; the final approval of NBC is 
awaited.  
 
Malawi has also expressed interest in accessing the CMD resistant cassava 
technology.  The discussions are underway between researchers in Malawi 
and Danforth to collaborate on this activity. Malawi has been designated as 
                                                 
23 Donald Danforth Plant Science Center: Team Members - Dr. Claude Fauquet, Dr. Nigel Taylor, Mr. Lawrence Kent, 
Dr. Elizabeth Vancil. Scientists from, KARI, CIAT and IITA are cooperating with Danforth scientists. 
24 For a discussion of cassava in Africa see Nweke, Spencer and Lynam (2002). Also see Fregene and Puoenti and 
Kaerlas (2002) for an overview of research on cassava biotechnology.   29
the lead country in the Southern Africa Region for a regional cassava 
biotechnology program funded by the USAID and coordinated by CIAT and 
Michigan State University.   
 
The short-term goals of the Danforth – KARI collaboration project is to 
conduct a field trial of transgenic cassava plants in KARI’s Alupe field 
station, and initiate the development of product commercialization package 
(PCP) for regulatory approvals.  This PCP will focus on East Africa and 
Kenya in particular. As additional funding becomes available, the PCPs will 
be expanded to include Nigeria and Malawi. The tentative timeline for the 
development and commercialization of CMD resistant transgenic cassava 
lines in Kenya is outlined below: 
 
•  Production of a Large Number of Plants (year 2006) 
•  Selecting the Best Plant Lines for Phase II Field Trials (year 2007) 
• Implementation  of  Phase  II Field Trials (year 2008) 
•  Final Field Trials and Selection of Two Best Transgenic Lines as 
Proposed Products (year 2009) 
•  Development of Full Biosafety Packages for Commercialization 
(2010) 
•  Licensing and Public Outreach  (year 2011) 
•  Multiplication of Planting Materials by KARI and others (year 2012) 
•  Monitoring and Measuring Impact (year 2013) 
 
In summary, biotechnology offers a promising approach to addressing the 
problem of cassava mosaic disease (CMD) – a serious production constraint 
that devastates one of Africa’s most important food staples.  Transgenic 
cassava plants developed at the Danforth Center have demonstrated strong 
resistance to CMD in greenhouse trials, and progress is being made to test 
this resistance in field trials in Kenya.  Improved genetic constructs have 
been produced and efficacy tested in a new generation of transgenic cassava 
plants.  Genetic transformation protocols are also being developed for high-
priority local cassava varieties in order to develop a product adapted to East 
African farmer needs.  Integration of optimized genetic constructs into East 
African germplasm will commence in late 2005 followed by screening for 
CMD resistance both in the greenhouse and the field.  The best performing 
cassava lines will become the subject of further study to generate required 
data on food and environmental safety. These data will form the basis for   30
regulatory review and approval, which will be followed by licensing, 
multiplication, and general release to farmers of the improved, transgenic 
planting materials by the year 2012.  GM cassava technology has potential to 
improve farmers’ productivity and livelihoods, but it is seven to eight years 
away from reaching the fields of smallholders in Africa. 
 
IV. LESSONS FROM THE CASE STUDIES AND FUTURE 
CHALLENGES 
 
Biotech crops have been grown commercially for a decade and they are now 
well established in Latin America and Asia but not in Africa, except for 
South Africa.  
The evidence reveals that some transgenic crops have delivered increased 
profits to farmers, reduced health problems and generated positive 
environmental effects in Latin America, Asia and South Africa. We now 
turn to our seven case studies and pose the question: What lessons can be 





1. Time and cost. The case studies have provided insights into the amount 
of time that it takes to develop GM crops, gain biosafety approvals and 
develop input delivery systems to get these products into the hands of 
smallholder farmers in Africa. A historical footnote is instructive on the time 
question.  In 1991 USAID signed a contract with Michigan State University 
to administer the Agricultural Biotech Support Project (ASBP). At that time, 
the managers of ASBP believed that two commodities—potato and 
cucurbits-could be commercialized in about six years of the life of the first 
ASBP contract. In a recent evaluation of ASBP I covering 1991-2004 life, 
Brenner (2004) concluded that instead of adopting a three to six year time 
frame, at least 10 to 15 years “should have been used as the norm” for the 
GM transformation research phase, biosafety approval and release of a GM 
product to farmers. Brenner concluded that the delay in getting the potato 
and cucurbit technology in the hands of farmers was mainly because of 
problems with the broad enabling environment, including policy and 
regulatory obstacles and weaknesses in input markets. The seven case 
studies in this paper support Brenner’s position that a working time frame of   31




The cost of the development of a GM variety has been higher than 
anticipated and expected to increase further because of the cost of lengthy 
field trials. The total cost ranges from $3 million to date for Bt potato to 
$700,000 for virus-resistant papaya, $4 million for herbicide resistance 
soyabeans and $2 million for Bt cotton in India. The costs of GM crop 
improvement are high for many small countries and need to be addressed 
through regional and international cooperation (Herdt 1991). 
 
2. Biosafety. A common theme cutting across the seven case studies is the 
delays in preparing national biosafety regulations and guidelines and getting 
them approved through the political process. It took Kenya five years from 
the time of signing the KARI/Monsanto agreement in 1991 to set up a 
National Biosafety Committee, and an additional two years to develop 
biosafety regulations. The case studies also reveal the need to maintain a 
strong national capacity to deal with new problems as they emerge. In the 
potato case study in South Africa, biosafety clearance was near completion 
when a new obstacle emerged: how to deal with the legal responsibility 
in case of environmental and health damage arising from the cross border 
movement of GM crops. The bottom line is the need to help Africa build its 
biosafety and regulatory capacity (Maredia et al 1999).  
 
3. Stages of GM Development. The case studies display the different 
capacities of national GM research programs and the need to tailor 
government and donor assistance to the stage of institutional development of 
each country and sub-region (Horstkotte and Byerlee 2000). The case studies 
reveal the diversity of agroecologies and the complexities of African diets, 
and call for research by social scientists on a range of topics, including 
diagnostic research to understand farmer adoption of GM crops (Smale and 
DeGroot 2003) and  consumer food preferences to guide GM research 
priorities.  For example, in Uganda there are more than 200 banana clones to 
satisfy local food preferences. Which local clones do plant breeders choose 
to use in GM research programs? 
                                                 
25 But a 10 to 15 year GM time frame should come at no surprise when it is compared with conventional plant breeding 
programs. It took Zimbabwe 28 years (1932 to 1960) of public sector-financed research before it hit the jackpot and 
produced the famous SR 52 maize hybrid that increased smallholder yields around 40 percent (Eicher 1995). Likewise 
it took Norman Borlaug twenty years of research on wheat in Mexico (1943-1963) before his high yielding wheat 
varieties were transferred to India in 1963 to form the foundation for the Green Revolution. And it took 14 years (1950-
1964) for Plowright to develop the famous Rinderpest cattle vaccine in Kenya.   32
 
4. Public Sector. Although African nations have requested donor aid for 
GM capacity building, donors have small budgets to support GM research as 
compared with the estimated $1.5 billion spent each year by private global 
plant science research companies. The CGIAR is only spending around $40 
million of its $430 million budget on biotechnology research for crops and 
livestock in 2005.
26 The World Bank assistance for biotechnology is 
embedded in agricultural technology and research projects. The cowpea case 
study is a classic example of the difficulty of mobilizing national and donor 
support for orphan crops such as cowpea, mung beans, teff, cucurbits and 
others. The cowpea researchers have set up an unpaid Secretariat but 
progress has been slow in mobilizing donor support. Fortunately, the AATF 
has agreed to facilitate the development of partnerships between cowpea 
research and companies owning some of the genes used in cowpea research. 
But despite the technological and marketing savvy of private multi-national 
firms, the private sector will thrive only if the public sector trains African 
scientists, conducts local plant breeding research, builds research 
laboratories, infrastructure, develops input markets and favorable economic 
policies. Both public and private investments are needed in GM R&D and 
the payoff to either public or private investments will be higher if they are 
coordinated  as complementary activities. 
 
5. Capacity Building. Cutting across all seven case studies are the problems 
of the brain drain, civil war, HIV/AIDS (Yamano and Jayne 2003) and other 
forms of human capital degradation (Ndulu 2004). For example, the 
University of Zimbabwe was a front-runner in setting up an MS program in 
biotechnology in the 1990s. A total of 63 students were trained over a ten-
year period but the program was terminated. Capacity building is a critical 
problem on the biotechnology agenda in African but the knowledge base on 
how to build and retain scientific, technical, and managerial capacity is 
disturbingly limited in Africa (World Bank 2005a). One of the critical 
capacity building problems is developing a plan to train the next generation 
of African scientists and figuring out how to expand GM research in 
Africa’s universities. USAID’s budget for GM activities in Africa does not 
include funds for long term (Phd) training. CORAF’s $25 million proposal 
for biotech/biosafety capacity building from 2005 to 2010 includes only $1 
million for training or only $200,000 per year (CORAF/WECARD 2004).  
                                                 
26 Lele (2003) contends, “The CGIAR lacks a system level policy, strategy or capacity for biotechnology and IPRs or 
public-private partnerships” (p.1123). See Morris and Hoisington (2000) for a discussion of the evolution of CGIAR 
thinking on research  on  GM crops and livestock.   33
 
6. Enabling Policies and Institutional Environment. Recent events in 
South Africa point up the importance of enabling policies (elimination of 
credit to smallholders to grow cotton, side selling, drought and lower world 
cotton prices) in reducing smallholder Bt cotton production over the past two 
years. A research team that studied smallholder Bt cotton in South Africa 
and initially declared it a success story now describe it as "a technological 
success and an institutional failure". The most important lesson from the 
South African experience is that "institutions matter". Research is urgently 
needed on how to develop institutions to address the seed, credit and 
marketing problems of smallholders (Rukuni et al 1998). These are the same 
issues that have slowed the adoption of smallholder hybrid maize in Africa 
(Byerlee and Eicher 1997). 
 
7. Synthesis of Case Studies. Table 1 summarizes the seven case studies, 
the years of GM research to date and the anticipated years of additional 
research required to reach a stage where GM varieties will be available to 
smallholders.  
 
Table 1. Seven case studies: Projections of the timeline for the release of 
GM crops to smallholder farmers in Africa
1 













potato  Kenya  Feathery Mottle 





Moth  1993  4 or more years 
Maize Kenya  Maize Stem 
Borers  1999  4 or more years  
Cotton  Major cotton 
growing countries  Cotton Bollworms  2000  5 or more years 
Banana Uganda  Banana Weevil 
and Diseases  2000  7 or more years 
Cowpea  West Africa  Pod Borer  2001  8 or more years 
Cassava  Kenya, Nigeria, 
Malawi 
Cassava Mosaic 
Virus  2001  8 or more years 
1.  Excluding South Africa where GM crops are now commercially grown by 
farmers. 
2.  Michigan State University Bt potato research with Egyptian scientists was 
discontinued in 2001.   34
 
 
CHALLENGES                          
 
1.  Raising Public Awareness of Biotechnology in Africa 
In many parts of Africa, there is confusion among the general public and 
decision makers about potential applications, benefits and risks of 
biotechnology products. There is a lot of misinformation, miscommunication 
and misperception about biotechnology products.  This has caused fear 
among the general public and policy makers and has made the decision 
process unduly slow and complex.  Therefore, there is an urgent need for 
each country to be able to tap global information sources to enable decision 
makers to analyze their own situation, make science-based decisions and 
capture the benefits from this new technology. 
 
Capacities will need to be developed to access, disseminate and 
communicate information related to biotechnology for agriculture.  For 
example, Zambia has established a Biotechnology Outreach Society of 
Zambia (BOSZ) to serve as a platform for an open dialogue among 
stakeholders on all issues related to biotechnology. The Public 
Understanding of Biotechnology (PUB) program of the Department of 
Science and Technology in South Africa is another example of effective 
communication with the public and various stakeholders 
(http://www.pub.ac.za/). Organizing learning events such as the workshops 
organized by the AfricaBio and the Africa Biotechnology Stakeholders 
Forum (ABSF) are good models for educating journalists and the media. 
   
2.  Building a National Biotechnology Strategy  
The governments of Africa need to develop a national biotechnology 
strategy that outlines a clear vision, priorities, commitment and various 
pathways to biotechnology R&D and human resource development. This 
strategy should define how biotechnology fits into the overall national 
agricultural research strategy, agricultural development strategy and target 
farmers and sectors where biotechnology tools will be applied based on the 
needs and priorities identified by various stakeholders. We have stressed the 
need to target biotechnology to increase the average cereal grain yields in 
Africa but recognize that the GM strategy for a particular country may give 
priority to increasing the production of Bt cotton, coffee or livestock. 
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3.  Developing Policies to Guide Regulatory, Legal and Technology 
Transfer Issues  
In spite of numerous studies and reports that document the safety of GM 
products developed through genetic engineering, a number of environmental 
and food safety issues have been raised. The environmental safety issues 
surrounding the use of biotechnology include gene flow/gene transfer, 
pest/pathogen effects, impacts on non-target and beneficial organisms, and 
development of pest resistance.  The food safety issues encompass toxicity, 
altered nutritional content of the genetically modified food products and 
their impact on human, and animal health. 
 
As biotechnology products move forward from laboratory to marketplace, 
they will require biosafety and food safety regulatory approvals from the 
national governments.  Food safety and biosafety assessments are expensive 
and require extensive laboratory and field studies/experiments.  The high 
costs of regulatory approvals have been the major factor hindering the 
commercialization of biotechnology products developed through the public 
sector.   
 
Further, the tools of modern biotechnology and genetic engineering are 
mostly proprietary and held by the private sector and laboratories in 
industrial countries.  Access to these proprietary technologies will require a 
capacity to negotiate and develop agreements.  The private sector 
increasingly wants to ensure that regulatory approvals are granted by the 
national governments before issuing a license to target a recipient country.  
Thus regulatory issues and IPR issues are closely tied together.  Therefore 
public private sector partnerships are of paramount importance for moving 
biotechnology forward in Africa. 
  
4. Capacity Building   
Biotechnology applications, utilization and management requires a diverse 
pool of well trained human resources, infrastructure/facilities for R&D, 
regulatory and legal policy framework, communication/outreach programs, 
and technology transfer/management support systems. Capacity building 
encompasses both institutional and human capacity building.  To take 
advantage of the wide spectrum of biotechnology tools, a country must 
pursue an integrated and comprehensive approach to capacity building 
(Figure 1).   
 
5.  Fostering Regional Cooperation in Biotechnology in Africa   36
Institutions in Africa and around the world are accumulating a wealth of 
experience and an information base on the use and management of 
biotechnology.  African scientists and policy makers can gain from the 
experiences of other countries and regions.  Regional networks and 
international cooperation are effective in sharing information, scientific and 
regulatory data, and expertise within specific geographic regions.  For 
example, environmental and food safety risk assessments are expensive, and 
countries may benefit from each other by sharing regulatory data and 
information. The advances in Internet technology now enable rapid and free 
delivery of information. One way to promote the culture of partnership and 
collaboration is to make it a requirement in the bidding for competitive 
biotechnology research grants.  For example, ASARECA, a sub-regional 
network in East Africa, is promoting regional collaboration and partnerships 
through its competitive research grant program.  
6. The African Agricultural Technology Foundation (AATF) was 
launched in June 2004 to broker royalty-free proprietary technologies for use 
in sub-Saharan Africa.  Initial activity has focused on five pilot projects of 
which three are focused on maize: Striga, insect resistant maize for Africa 
(IRMA) and pro-vitamin A enhancement in maize. It is estimated that the 
damage caused by Striga on maize annually is $1 billion and affects more 
than 100 million people in sub-Saharan Africa.  
 
V. CONCLUSIONS 
We have argued that agricultural biotechnology has the potential to 
help African smallholders and also confer benefits to consumers, the 
environment and health of farmers and farm workers. However, many 
African decision makers are requesting more information on potential 
environmental and food safety issues related to GM products. Ten 
major points summarize our conclusions: 
 
1. GM crops have now been commercialized for a decade and they are 
producing benefits to farmers, consumers and the environment, especially in 
Asia, Latin America and South Africa. The global area under GM crops 
grew by 20 percent in 2004, illustrating widespread farmer acceptance. 
However, South Africa is the only country in Africa that is growing GM 
crops commercially. However, many countries in Africa are utilizing tissue 
culture in their research and others have GM products in the pipeline.  
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2. Fifty two of the 53 countries in Africa are not growing GM crops 
commercially. The seven case studies have revealed a variety of reasons and 
barriers responsible for Africa’s delayed response, including scientific, 
technical, political and institutional factors and a limited pool of scientific, 
managerial, legal, regulatory and entrepreneurial talent. Food aid and trade 
fears are common in southern Africa because of drought from 2002 to 2005 
and the need to import food aid or commercial grain imports. 
 
3. The seven case studies have revealed an underestimation of the time 
required and the cost of developing and field testing a GM crop and securing 
regulatory approval for moving it from the laboratory to the fields of 
farmers. Instead of taking 5 to 7 years (a common estimate in the early 
nineties), the seven case studies show that it might take a total of 10 to 15 
years to develop GM crops, create regulatory systems and field test, and 
deliver GM cultivars to smallholders. 
 
4. There is a need to develop a national and regional capacity to monitor 
potential health, environmental, distributive, food safety risks and cross 
border movement of GM cultivars, especially when neighboring countries 
do not have functional regulatory systems in place.  
 
5. Bt cotton is a global success story in terms of reducing the amount of 
pesticides and labor inputs and increases in yields and farm incomes. The 
new knowledge embodied in the Bt gene has substituted for resources (labor 
and the capital cost of pesticides) to control the cotton bollworm. The 
positive environmental effects of Bt cotton have moderated the voices of the 
anti-GM lobbies and spurred African Heads of State and Ministers of 
Agriculture to allow Bt cotton trials to be grown in seven countries in 
Africa. However, there is an air of uncertainty surrounding Bt cotton in 
South Africa. In 1999 Bt cotton was rapidly adopted by smallholders but 
after a few years the curtailment of credit to smallholders, drought and 
declining world cotton prices contributed to a decline in smallholder cotton 
production. Smallholder Bt cotton in South Africa has recently been 
described as a technological triumph and an “institutional failure”. The rise 
and decline of smallholder Bt cotton in South Africa should be carefully 
studied by African nations where cotton field trials are underway. 
 
 
6. GM research should be embedded into African plant and animal 
improvement  programs that facilitate interaction and cooperation between   38
plant breeders and GM specialists. However, since donor support is 
increasingly targeted to GM crop research rather than conventional plant 
breeding programs, it is proving difficult to attract African students to 
pursue postgraduate training in crop science and plant breeding in African 
universities. While the private sector is increasingly taking over breeding 
internationally, African universities will have to play a key role not only in 
training future plant breeders but also in helping government researchers 
carry out research on orphan crops such as teff, mung beans, cowpea and 
other crops. 
 
7. Capacity Building is basically an accretionary (step by step) process that 
unfolds slowly and almost invisibly over time. Because of the shortage of 
well trained human resources in Africa, especially in legal and regulatory 
matters, trade, and biosafety, donors should invest heavily in long term 
training of scientists. 
 
8. Premature success stories. There is a growing number of optimistic 
scenarios of the projected of GM crops. However, in some cases these are 
based on a small sample of farmers covering a two to three years of field 
trials. The early reports on the “success” of smallholder Bt cotton in South 
Africa illustrates the need for caution in drawing conclusion from a small 
sample of farmers covering a few years of experience. Likewise, some 
African countries have been over enthusiastic about when GM crops would 
be ready for release. In some cases these predictions have been followed by 
years of delay in getting a functioning regulatory system in place. 
 
9. Since GM crop development in Africa is in its infancy, donors and 
foundations can play a strategic role in supporting long term public sector 
investments in capacity building (human capital and infrastructure), carrying 
out risk assessments and supporting institutional innovations such as the 
AATF and sub-regional GM networks. Special attention should be given to 
the “small country” problem. Donors should refrain from encouraging 
organizations such as NEPAD, FARA, the AATF or the CGIAR to develop 
an African GM strategy. Because of the sharp differences in agroecologies 
and stage of development, the logical place for developing GM strategies 
and partnerships is at the national and sub-regional levels such as regional 
sub-committees on GMOs.  
 
10. We end with the critical question of investment priorities .We have 
argued that raising the average cereal yield is the overarching problem to be   39
addressed by agricultural researchers in Africa over the next ten to twenty 
years. This is especially urgent in a continent with an average rate of 
population growth of 2.8 percent, which implies a doubling of population in 
25 years. The logical question that flows from rapid population growth and 
stagnant cereal yields is whether African governments and private seed 
companies should invest in plant breeding or GM research to raise cereal 
yields. The quick answer points to expanded investment in GM research in 
Africa because the global area under GM crops grew by 20 percent in 2004 
alone. This is reinforced by increasing donor support for sub regional 
meetings and workshops on biotechnology and biosafety in Africa. But the 
seven case studies summarized in Table 1 reveal an underestimation of the 
time, cost, risks and unforeseen political and policy problems associated 
with the development of GM food crops at this early stage of African’s 
economic history and institutional maturity. 
 
 Without question, the results of the case studies focus the attention of policy 
makers, economists and donors on the key question: what is the cheapest 
source of new cereal crop technology in Africa in the medium term (10 to 15 
years): old fashioned plant breeding or GM research? The data show that the 
past rate of return on plant breeding research by the CGIAR and NARS in 
Africa is around 20 to 30 percent or higher per year, an impressive statistic 
(Evenson and Gollin 2003).
27  
 
The results of the case studies and global experience suggest that African 
governments should pursue three mutually supporting scientific pathways to 
crop improvement and raising food crop yields:(1) give immediate and 
sustained priority to investing in strengthening plant breeding research in 
African NARS , universities and the CGIAR, (2) strengthen African capacity 
in biosafety, IPR, regulatory procedures, WTO, and research on institutional 
innovations to develop efficient seed and fertilizer input delivery systems 
and (3) invest in long term training programs for African scientists to enable 
them to become efficient borrowers of GM research from other counties in 
the world and progressively build their own scientific capacity to eventually 
carry out GM research in Africa. But the evidence suggests that old- 
fashioned plant breeding research from national breeding programs, 
universities, private seed companies and the CGIAR will be the primary 
source of increased cereal yields in Africa in the foreseeable future, i.e. until 
2015 to 2020 
                                                 
27 There is still not enough evidence to generalize about the returns to GM crop improvement research. See the 
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ANNEX 1. Biotech Websites 
International Resources in Biotechnology  
 
I. General Resources 
 
USAID – Agricultural Biotechnology Support Project II (ABSP II): 
http://www.absp2.cornell.edu/ 
 
USAID – Program for Biosafety Systems (PBS): 
http://www.ifpri.org/themes/pbs/pbs.htm 
 
The Biosafety Information Network and Advisory Service (BINAS),  
United Nations Industrial Development Organization (UNIDO): 
http://binas.unido.org/binas/ 
 




International Service for the Acquisition of Agri-biotech Applications (ISAAA): 
http://www.isaaa.org/ 
 
The Consultative Group on International Agricultural Research (CGIAR): 
http://www.cgiar.org 
 
The Food and Agriculture Organization (FAO):  http://www.fao.org/biotech/act.asp 
 
African Biotechnology Stakeholders Forum (ABSF): http://www.absfafrica.org/ 
 
African Agricultural Technology Foundation (AATF): http://www.aftechfound.org/ 
 
African Journal of Biotechnology: http://www.academicjournals.org/AJB 
 
Biotechnology Trust Africa (BTA):  http://www.africabio.com/status/bta.htm 
 
Biosciences Eastern and Central Africa (BECA): http://www.biosciencesafrica.org 
 
USDA – FAS (Biotechnology Group): http://www.fas.usda.gov/itp/biotech/index.html 
 
The World Bank: http://www.worldbank.org/ 
 
CABI AgBioechNet: http://www.agbiotechnet.com 
 
The Donald Danforth Plant Science Center, St. Louis, USA: 
http://www.danforthcenter.org/   49
 




World Technology Access Program (WorldTAP), Michigan State University:  
www.iia.msu.edu/worldtap.html 
 
BIO-EARN -  http://www.bio-earn.org/why-bioearn.html 
 
Plant Biotechnology Institute for Developing Countries (IPBO), University of Ghent, 
Belgium: http://www.ipbo.rug.ac.be 
 
Information Systems for Biotechnology: http://www.isb.vt.edu/ 
 








II. Biosafety Resources 
 
USAID Program for Biosafety Systems - http://www.ifpri.org/themes/pbs/pbs.htm 
 
AGBIOS - http://www.agbios.com/main.php 
 
ICGEB (International Center for Genetic Engineering and Biotechnology) -
http://www.icgeb.trieste.it/ 
 
European Biosafety Association (EBSA) - http://www.ebsa.be/ 
 
General Biosafety Resources - 
http://www.jiwlp.com/contents/biosafety_resources_net.html 
 
Pew Initiative in Food and Biotechnology - http://pewagbiotech.org/ 
 
UNEP-GEF Biosafety Program - http://www.unep.ch/biosafety/ 
 
USDA-APHIS – Biotechnology Regulatory Service (BRS) - 
http://www.aphis.usda.gov/brs/ 
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NIH guidelines for Research Involving Recombinant DNA Molecules - 
http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html 
 
University of Tennessee Biosafety website - http://biosafety.utk.edu/plant.htm 
 
Biosafety News - http://www.biosafetynews.com/ 
 
Information Systems for Biotechnology – http://gophisb.biochem.vt.edu/ 
 
Biosafety Workbook (MSU/IIA web site) ABSP I - 
http://www.iia.msu.edu/absp/biosafety_workbook.html 
 
Environmental Biosafety Research - 
http://www.edpsciences.org/journal/index.cfm?edpsname=ebr 
 
Biosafety Journal - http://www.bioline.org.br/by 
 
Essential Biosafety - http://www.essentialbiosafety.info/main.php  
 
The Biosafety Information Network and Advisory Service (BINAS) - 
http://binas.unido.org/binas/ 
 
Cartagena Protocol in Biosafety - http://www.biodiv.org/biosafety/ 
 
III.  Intellectual Property Rights and Technology Transfer Resources  
 
International Union for the Protection of New Varieties of Plants (UPOV):  
http://www.upov.int 
 
World Intellectual Property Organization (WIPO): http://www.wipo.int 
 
World Trade Organization (WTO): http://www.wto.org 
 
The International Association for the Protection of Intellectual Property (AIPPI):  
http://www.aippi.org/aims.html 
 
Association of University Technology Managers (AUTM): http://www.autm.net 
 
Licensing Executive Society (LES): http://les.org 
 
PIPERS Virtual Intellectual Property Library: Gateway to IP offices across the world:  
http://www.piperpat.co.nz 
 
World Technology Access Program (WorldTAP), Michigan State University:  
http://www.iia.msu.edu/worldtap.htm 
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Franklin Pierce Law Center:  http://www.fplc.edu 
 
Strategic World Initiative for Technology Transfer: http://www.swiftt.cornell.edu 
 
Intellectual Property Rights in Agricultural Biotechnology – Biotechnology in 
Agriculture Series, No.28: http://www.cabi-publishing.org/ 
 
Intellectual Property Rights in Animal Breeding and Genetics: http://www.cabi-
publishing.org/ 
 
USDA Plant Variety Protection Office: http://www.ams.usda.gov/science/pvpo/pvp.htm 
 
U.S. Patent and Trademark Office: http://www.uspto.gov 
 




IV. Food Safety Resource List 
 
World Health organization – Biotechnology (GM Food) - 
http://www.who.int/foodsafety/biotech/en/ 
 
FAO/WHO Biotechnology and Food Safety – 
http://fao.org/es/esn/food/risk_biotech_en.stm 
 
Codex Task Force on Food Derived from Biotechnology 
http://fao.org/codex/ALINORM01/al01_34e.pdf 
Organization for Economic co-operation and Development (OECD) Biotechnology – 
http://www.oecd.org 
Pew Initiative on Food & Biotechnology: http://www.pewagbiotech.org 
Royal Society (London). Genetically Modified Plants for Food Use and Human Health – 
an update. Policy Document 4/02:  http://www.royalsoc.ac.uk 
National Food Safety and Toxicology Center, Michigan State University – 
www.foodsafe.msu.edu 
 
International Food Information Council (IFIC): www.ific.org    
 
Asian Food Information Center (AFIC) - www.afic.org 
  
Gateway to U.S. Government Food Safety Information -   52
http://www.foodsafety.gov/~fsg/biotech.html 
  
Institute of Food Science and Technology (IFST) - http://www.ifst.org/hottop10.htm 
 
International Food Information Council/FDA. Food Risks: Perception vs. Reality. 
http://vm.cfsan.fda.gov/~dms/risk-toc.html 
 
USDA Food Safety Research Information Office 
http://www.nal.usda.gov/fsrio/ 
 
U.S.  Food and Drug Administration - http://www.fda.gov/ 
 
USDA Food and Nutrition Information Center 
http://www.nal.usda.gov/fnic/ 
 
The Pan American Health Organization (PAHO) - http://www.paho.org/ 
 
World Organization for Animal Health - Office International des Epizooties (OIE) - 
http://www.oie.int/eng/en_index.htm 
AgBiosafety - University of Nebraska - http://agbiosafety.unl.edu/ 
 
V. Biotechnology Communication Resources 
 
CropBiotech Net – Weekly summary of world developments in agri-biotech for 
developing countries – http://www.isaaa.org/kc 
 
International Service for the Acquisition of Agri-Biotech Applications (ISAAA) – 
Knowledge Center - http://www.isaaa.org/kc 
 
Biotechnology Technical Information Services – http://www.tiskmutt.org 
 
AfricaBio - http://www.africabio.org 
 
SEAMEO SEARCA Biotechnology Information Center (Philippines) - 
http://www.searca.org/~bic 
 
Public Understand if Biotechnology (PUB) – South Africa. http://www.pub.ac.za/  
 